Hydrophobic protein in colorectal cancer in relation to tumor stages and grades

Yeoh, Lay-Chin; Loh, Chee-Keat; Gooi, Boon-Hui; Singh, Manjit; Gam, Lay‐Harn

doi:10.3748/wjg.v16.i22.2754

Cited by 8 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Altered expression of membrane proteins in several CRC samples was found using the 2D-DIGE technique. Among these proteins, annexin A4 and voltage-dependent anion channel (VDAC) were proposed by the authors as promising biomarkers for CRC diagnosis and response to therapy [ 102 ].…”

Section: Discussionmentioning

confidence: 99%

Predicting Response to Neoadjuvant Therapy in Colorectal Cancer Patients the Role of Messenger-and Micro-RNA Profiling

Izzotti

Ceccaroli

Geretto

et al. 2020

Cancers

View full text Add to dashboard Cite

Colorectal cancer patients’ responses to neoadjuvant therapy undergo broad inter-individual variations. The aim of this systematic review is to identify a molecular signature that is predictive of colon cancer downstaging and/or downgrading after neoadjuvant therapy. Among the hundreds analysed in the available studies, only 19 messenger-RNAs (mRNAs) and six micro-RNAs (miRNAs) were differentially expressed in responders versus non-responders in two or more independent studies. Therefore, a mRNA/miRNA signature can be designed accordingly, with limitations caused by the retrospective nature of these studies, the heterogeneity in study designs and the downgrading/downstaging assessment criteria. This signature can be proposed to tailor neoadjuvant therapy regimens on an individual basis.

show abstract

Section: Discussionmentioning

confidence: 99%

Predicting Response to Neoadjuvant Therapy in Colorectal Cancer Patients the Role of Messenger-and Micro-RNA Profiling

Izzotti

Ceccaroli

Geretto

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…STOML2 has been identified as an oncogenic-related protein and found to be upregulated in multi-cancers. First, STOML2 might serve as a prognostic marker especially in human gallbladder cancer, gastric cancer, glioma, colorectal cancer, breast cancer, and pulmonary squamous cell carcinoma (19)(20)(21)(22)(23)(24). STOML2 is also involved in invasion, regulating cell growth and cell adhesion in human esophageal squamous cell carcinoma, glioma, and human endometrial adenocarcinoma (21,(25)(26)(27).…”

Section: Discussionmentioning

confidence: 99%

Gene Expression Profiling of Desmoid Tumors by cDNA Microarrays and Correlation with Progression-Free Survival

Salas

Brulard

Terrier

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Because desmoid tumors exhibit an unpredictable clinical course, translational research is crucial to identify the predictive factors of progression in addition to the clinical parameters. The main issue is to detect patients who are at a higher risk of progression. The aim of this work was to identify molecular markers that can predict progression-free survival (PFS).Experimental Design: Gene-expression screening was conducted on 115 available independent untreated primary desmoid tumors using cDNA microarray. We established a prognostic gene-expression signature composed of 36 genes. To test robustness, we randomly generated 1,000 36-gene signatures and compared their outcome association to our define 36-genes molecular signature and we calculated positive predictive value (PPV) and negative predictive value (NPV).Results: Multivariate analysis showed that our molecular signature had a significant impact on PFS while no clinical factor had any prognostic value. Among the 1,000 random signatures generated, 56.7% were significant and none was more significant than our 36-gene molecular signature. PPV and NPV were high (75.58% and 81.82%, respectively). Finally, the top two genes downregulated in no-recurrence were FECH and STOML2 and the top gene upregulated in no-recurrence was TRIP6.Conclusions: By analyzing expression profiles, we have identified a gene-expression signature that is able to predict PFS. This tool may be useful for prospective clinical studies.

show abstract

“…Others have been identified from membrane CRC fractions by iTRAQ [ 248 ]. Although approaches such as 2D-DIGE and mass spectrometry have led to the discovery of a number of differentially expressed proteins in CRC [ 5 – 8 , 10 – 12 , 257 , 258 ], the prognostic significance of these molecules and their contribution to cancer growth and metastasis has not always been easy to establish. Hence very few of these proteins have found clinical utility either as prognostic markers or therapeutic targets.…”

Section: Crc Translational Proteomics Researchmentioning

confidence: 99%

Cell Surface Markers in Colorectal Cancer Prognosis

Belov

Zhou

Christopherson

2010

IJMS

View full text Add to dashboard Cite

The classification of colorectal cancers (CRC) is currently based largely on histologically determined tumour characteristics, such as differentiation status and tumour stage, i.e., depth of tumour invasion, involvement of regional lymph nodes and the occurrence of metastatic spread to other organs. These are the conventional prognostic factors for patient survival and often determine the requirement for adjuvant therapy after surgical resection of the primary tumour. However, patients with the same CRC stage can have very different disease-related outcomes. For some, surgical removal of early-stage tumours leads to full recovery, while for others, disease recurrence and metastasis may occur regardless of adjuvant therapy. It is therefore important to understand the molecular processes that lead to disease progression and metastasis and to find more reliable prognostic markers and novel targets for therapy. This review focuses on cell surface proteins that correlate with tumour progression, metastasis and patient outcome, and discusses some of the challenges in finding prognostic protein markers in CRC.

show abstract

Hydrophobic protein in colorectal cancer in relation to tumor stages and grades

Abstract: Stomatin-like protein 2 was found to be a promising biomarker for CRC, especially in female patients. The differentially expressed proteins identified were associated with CRC and may act as drug target candidates.

Cited by 8 publications

References 29 publications

Predicting Response to Neoadjuvant Therapy in Colorectal Cancer Patients the Role of Messenger-and Micro-RNA Profiling

Predicting Response to Neoadjuvant Therapy in Colorectal Cancer Patients the Role of Messenger-and Micro-RNA Profiling

Gene Expression Profiling of Desmoid Tumors by cDNA Microarrays and Correlation with Progression-Free Survival

Cell Surface Markers in Colorectal Cancer Prognosis

Contact Info

Product

Resources

About